SCHEMBL5866205

SCHEMBL5866205

N/N=C\c1ccc(CCSc2ccccc2NS(=O)(=O)c2cc(Cl)c(Cl)cc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GUSB P08236 1/20 0.55
CA12 O43570 4/20 0.41
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
CA3 P07451 4/20 0.41
CA6 P23280 4/20 0.41
CA7 P43166 4/20 0.41
CA9 Q16790 4/20 0.41
CA13 Q8N1Q1 4/20 0.41
CA14 Q9ULX7 4/20 0.41
CA5B Q9Y2D0 4/20 0.41
CA4 P22748 3/20 0.41
CA5A P35218 3/20 0.40
NOD2 Q9HC29 1/20 0.37
PGR P06401 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5866211 1.00 GUSB (0.55) GUSBCA12CA1CA2CA3
SCHEMBL5866287 0.90 NOD2 (0.47) GUSBCA12CA1CA2CA3
SCHEMBL5866291 0.90 NOD2 (0.47) GUSBCA12CA1CA2CA3
SCHEMBL5866219 0.89 CCR2 (0.42) GUSBCA12CA1CA2CA3
SCHEMBL5866227 0.89 CCR2 (0.42) GUSBCA12CA1CA2CA3
SCHEMBL5866378 0.86 GAA (0.46) GUSBCA12CA1CA2CA9
SCHEMBL5866368 0.86 GAA (0.46) GUSBCA12CA1CA2CA9
SCHEMBL5866209 0.83 ALDH1A1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL5866204 0.83 ALDH1A1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL5866217 0.82 MCL1 (0.38) GUSBCA12CA1CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074820-B2 Amidino derivatives and their use as thrombin inhibitors ASTRAZENECA AB (SE) 2006-07-11 US claimed
EP-0917528-B1 NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2002-09-18 EP claimed
US-20020040043-A1 Amidino derivatives and their use as thrombin inhibitors ANTONSSON THOMAS (SE) 2002-04-04 US claimed
US-6221898-B1 ANTICOAGULANTS ASTRA AKTIEBOLAG (SE) 2001-04-24 US claimed
EP-0917528-B1 NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2002-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040043-A1 Amidino derivatives and their use as thrombin inhibitors SERPINC1, F2, SERPINE1 GUSB 1444/4885CA12 3603/4885CA1 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.